Monalizumab

Monalizumab, a humanized anti-NKG2A antibody(formerly IPH2201) is an investigational drug being studied for rheumatoid arthritis, gynecologic malignancies[1] and other cancers.[2][3]

Monalizumab
Monoclonal antibody
Type?
SourceHumanized
TargetNKG2A
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
ChemSpider
  • none
UNII

Mechanism of action

Monalizumab is a monoclonal antibody targeted at NKG2A.[4] It is a checkpoint inhibitor.[5][6]

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.